These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 34265103)

  • 21. Two Cases of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with High Serum Procalcitonin Levels, Including the First Case Complicated with Adrenal Hemorrhaging.
    Nara M; Komatsuda A; Itoh F; Kaga H; Saitoh M; Togashi M; Kameoka Y; Wakui H; Takahashi N
    Intern Med; 2017; 56(10):1247-1252. PubMed ID: 28502946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review.
    Shirai T; Onishi A; Waki D; Saegusa J; Morinobu A
    Medicine (Baltimore); 2018 Jun; 97(23):e11045. PubMed ID: 29879072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic basis for iMCD-TAFRO.
    Yoshimi A; Trippett TM; Zhang N; Chen X; Penson AV; Arcila ME; Pichardo J; Baik J; Sigler A; Harada H; Fajgenbaum DC; Dogan A; Abdel-Wahab O; Xiao W
    Oncogene; 2020 Apr; 39(15):3218-3225. PubMed ID: 32051554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TAFRO syndrome is associated with anti-SSA/Ro60 antibodies, in contrast to idiopathic castleman disease.
    Shirakashi M; Nishida Y; Nakashima R; Fujimoto M; Hiwa R; Tsuji H; Kitagori K; Akizuki S; Morinobu A; Yoshifuji H
    Sci Rep; 2024 Feb; 14(1):2889. PubMed ID: 38311632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
    Phillips AD; Kakkis JJ; Tsao PY; Pierson SK; Fajgenbaum DC
    J Cell Mol Med; 2022 Jun; 26(11):3147-3152. PubMed ID: 35488725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
    Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
    Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TAFRO syndrome: A severe manifestation of Sjogren's syndrome? A systematic review.
    Grange L; Chalayer E; Boutboul D; Paul S; Galicier L; Gramont B; Killian M
    Autoimmun Rev; 2022 Aug; 21(8):103137. PubMed ID: 35803499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tafro syndrome: Critical review for clinicians and pathologists.
    Paydas S
    Crit Rev Oncol Hematol; 2018 Aug; 128():88-95. PubMed ID: 29958635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tacrolimus Treatment for TAFRO Syndrome.
    Shirai T; Ichikawa S; Saegusa J
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38791031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TAFRO Syndrome: Guidance for Managing Patients Presenting Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly.
    Miura K; Nishimaki-Watanabe H; Takahashi H; Nakagawa M; Otake S; Hamada T; Koike T; Iizuka K; Takeuchi Y; Kurihara K; Endo T; Ito S; Nukariya H; Namiki T; Hayashi Y; Nakamura H
    Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.
    Iwaki N; Gion Y; Kondo E; Kawano M; Masunari T; Moro H; Nikkuni K; Takai K; Hagihara M; Hashimoto Y; Yokota K; Okamoto M; Nakao S; Yoshino T; Sato Y
    Sci Rep; 2017 Feb; 7():42316. PubMed ID: 28205564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
    Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L
    Front Immunol; 2019; 10():1489. PubMed ID: 31316523
    [No Abstract]   [Full Text] [Related]  

  • 33. Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
    Bustamante MS; Pierson SK; Ren Y; Bagg A; Brandstadter JD; Srkalovic G; Mango N; Alapat D; Lechowicz MJ; Li H; Van Rhee F; Lim MS; Fajgenbaum DC
    Haematologica; 2024 Jul; 109(7):2196-2206. PubMed ID: 38205523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr Virus-Positive Cutaneous and Systemic Plasmacytosis with TAFRO Syndrome-like Symptoms Successfully Treated with Rituximab.
    Kakiuchi S; Akiyama H; Harima I; Takagi I; Rikitake J; Kozuki Y; Inaba M; Fujiwara H; Kurose N; Yamada S; Masaki Y
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Guo X; Shioya A; Mizutani KI; Kumagai M; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Nakamura S; Yamada S
    Pathol Res Pract; 2019 Oct; 215(10):152563. PubMed ID: 31358479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
    Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
    Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Castleman disease].
    Meignin V; Calvani J; Oksenhendler E
    Ann Pathol; 2023 Jan; 43(1):13-24. PubMed ID: 36192235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
    Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
    Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
    Pai RL; Japp AS; Gonzalez M; Rasheed RF; Okumura M; Arenas D; Pierson SK; Powers V; Layman AAK; Kao C; Hakonarson H; van Rhee F; Betts MR; Kambayashi T; Fajgenbaum DC
    JCI Insight; 2020 May; 5(9):. PubMed ID: 32376796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology.
    Simeni Njonnou SR; Deuson J; Royer-Chardon C; Vandergheynst FA; Wilde V
    BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32606113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.